ASCO 2015 | Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
Jean-Jacques Kiladjian
Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.
Related videos
2:14
Key population-based registry studies in hematological oncology
Magnus Björkholm
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:30
LCL161 for primary myelofibrosis: a new therapy in the field
Naveen Pemmaraju
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
1:25
Highlights on myelofibrosis from ASH
Claire Harrison
